Specialists highlight that genetic testing of embryos can help avoid unsuccessful treatment attempts and provide valuable information for patients with recurrent miscarriage or recurrent implantation failure

VALENCIA, Spain, June 30, 2026 /PRNewswire/ -- Achieving pregnancy through assisted reproduction may require more than one treatment cycle, and in some cases underlying chromosomal or genetic abnormalities may prevent embryo implantation or the successful progression of pregnancy.

To better understand these situations, reproductive medicine now offers advanced tools such as Preimplantation Genetic Testing for Aneuploidy (PGT-A), a technique that analyses embryos before transfer to identify chromosomal abnormalities that may compromise implantation or the normal development of pregnancy.

According to Dr Jakob Doblinger, gynaecologist at IVI Valencia, this information can be particularly valuable for patients with recurrent miscarriage, recurrent implantation failure, advanced maternal age or known genetic conditions. "PGT-A provides additional information before embryo transfer and, in selected patients, can help avoid treatment attempts with a low chance of success while allowing us to personalise the reproductive strategy," explains Dr Doblinger.

With more than 35 years of experience in treating complex infertility cases, IVI routinely performs PGT-A as part of its personalised approach to reproductive medicine. The technique helps identify embryos with chromosomal abnormalities that are unlikely to result in a healthy pregnancy, reducing unsuccessful embryo transfers and the emotional burden associated with repeated failed treatments.

Approximately 15–20% of patients attending IVI have experienced previous implantation failure.

"When pregnancy is not achieved after several treatment attempts, it is essential to understand the factors that may be affecting the process. Today we have far more precise diagnostic tools that allow us to evaluate each case individually," adds Dr Doblinger.

The role of PGT-A in complex fertility cases

The availability of certain genetic tests varies across Europe. In Germany, for example, preimplantation genetic testing is only permitted under very limited circumstances and is subject to strict legal regulation.

As a result, many patients from countries such as Germany travel to IVI clinics each year to undergo PGT-A as part of their fertility treatment, enabling embryo selection based on genetic information before transfer.

"Spain has become one of Europe's leading destinations for assisted reproduction thanks to the expertise of its medical teams, access to advanced technologies and the development of highly personalised diagnostic and treatment strategies. At IVI, PGT-A is one of the tools we use to assess selected fertility treatments," says Dr Doblinger.

In addition, IVI offers online consultations that allow much of the treatment process to be managed remotely, reducing the need for travel while maintaining close coordination with each patient's local medical team. This ensures personalised follow-up throughout every stage of treatment.